<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="myc70069" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mycoses</journal-id><journal-id journal-id-type="iso-abbrev">Mycoses</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1439-0507</journal-id><journal-id journal-id-type="publisher-id">MYC</journal-id><journal-title-group><journal-title>Mycoses</journal-title></journal-title-group><issn pub-type="ppub">0933-7407</issn><issn pub-type="epub">1439-0507</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40396391</article-id><article-id pub-id-type="pmc">PMC12093445</article-id><article-id pub-id-type="doi">10.1111/myc.70069</article-id><article-id pub-id-type="publisher-id">MYC70069</article-id><article-id pub-id-type="other">MYC-OR-2025-080.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Efinaconazole 10% Topical Solution for Treatment of Onychomycosis in Older Adults: A Post Hoc Analysis of Two Phase 3 Randomised Trials</article-title></title-group><contrib-group><contrib id="myc70069-cr-0001" contrib-type="author" corresp="yes"><name><surname>Lipner</surname><given-names>Shari R.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5913-9304</contrib-id><xref rid="myc70069-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>shl9032@med.cornell.edu</email></address></contrib><contrib id="myc70069-cr-0002" contrib-type="author"><name><surname>Gupta</surname><given-names>Aditya K.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8664-7723</contrib-id><xref rid="myc70069-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="myc70069-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="myc70069-cr-0003" contrib-type="author"><name><surname>Joseph</surname><given-names>Warren S.</given-names></name><xref rid="myc70069-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="myc70069-cr-0004" contrib-type="author"><name><surname>Elewski</surname><given-names>Boni</given-names></name><xref rid="myc70069-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="myc70069-cr-0005" contrib-type="author"><name><surname>Guenin</surname><given-names>Eric</given-names></name><xref rid="myc70069-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="myc70069-cr-0006" contrib-type="author"><name><surname>Vlahovic</surname><given-names>Tracey C.</given-names></name><xref rid="myc70069-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="myc70069-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Weill Cornell Medicine</institution>
<city>New York</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><aff id="myc70069-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Mediprobe Research Inc.</institution>
<city>London</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="myc70069-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Division of Dermatology, Temerty Faculty of Medicine, Department of Medicine</named-content>
<institution>University of Toronto</institution>
<city>Toronto</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="myc70069-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Arizona College of Podiatric Medicine</named-content>
<institution>Midwestern University</institution>
<city>Glendale</city>
<named-content content-type="country-part">Arizona</named-content>
<country country="US">USA</country>
</aff><aff id="myc70069-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>University of Alabama at Birmingham School of Medicine</institution>
<city>Birmingham</city>
<named-content content-type="country-part">Alabama</named-content>
<country country="US">USA</country>
</aff><aff id="myc70069-aff-0006">
<label>
<sup>6</sup>
</label>
<institution>Ortho Dermatologics, a division of Bausch Health US, LLC</institution>
<city>Bridgewater</city>
<named-content content-type="country-part">New Jersey</named-content>
<country country="US">USA</country>
</aff><aff id="myc70069-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Samuel Merritt University College of Podiatric Medicine</institution>
<city>Oakland</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Shari R. Lipner (<email>shl9032@med.cornell.edu</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><volume>68</volume><issue seq="193">5</issue><issue-id pub-id-type="doi">10.1111/myc.v68.5</issue-id><elocation-id>e70069</elocation-id><history>
<date date-type="rev-recd"><day>02</day><month>5</month><year>2025</year></date>
<date date-type="received"><day>07</day><month>3</month><year>2025</year></date>
<date date-type="accepted"><day>07</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Wiley&#x02010;VCH GmbH. Published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Mycoses</italic> published by Wiley&#x02010;VCH GmbH.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:MYC-68-e70069.pdf"/><abstract><title>ABSTRACT</title><sec id="myc70069-sec-0001"><title>Background</title><p>Onychomycosis is common in older adults and can be difficult to treat owing to slower nail growth, increased nail thickness, comorbidities, and concomitant medications. Oral treatments can be complicated by contraindications, drug&#x02013;drug interactions, and adverse effects. Topical treatments such as efinaconazole 10% solution may be beneficial for treating older adults.</p></sec><sec id="myc70069-sec-0002"><title>Objectives</title><p>To evaluate the efficacy/safety of efinaconazole 10% solution in adults aged &#x02265;&#x02009;65&#x02009;years with toenail onychomycosis.</p></sec><sec id="myc70069-sec-0003"><title>Patients/Methods</title><p>In two multicenter, double&#x02010;blind, phase 3 studies (NCT01008033; NCT01007708), patients with mild to moderate toenail onychomycosis were randomised (3:1) to once&#x02010;daily efinaconazole or vehicle for 48&#x02009;weeks, with a 4&#x02010;week follow&#x02010;up. Pooled data for participants aged &#x02265;&#x02009;65&#x02009;years were analysed post hoc (<italic toggle="no">n</italic>&#x02009;=&#x02009;162 efinaconazole, <italic toggle="no">n</italic>&#x02009;=&#x02009;56 vehicle). The primary endpoint was complete cure (0% involvement of target toenail plus mycologic cure [negative KOH and fungal culture]) at week 52. Treatment&#x02010;emergent adverse events (TEAEs) were assessed throughout.</p></sec><sec id="myc70069-sec-0004"><title>Results</title><p>At week 52, a significantly greater proportion of older adults (aged 65&#x02013;71&#x02009;years) achieved complete cure with efinaconazole than vehicle (13.6% vs. 3.6%; <italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.05). Complete/almost complete cure rate was also significantly greater (&#x02264;&#x02009;5% involvement and mycologic cure; 19.1% vs. 5.4%; <italic toggle="no">p</italic>&#x02009;=&#x02009;0.01), and over half (59.2%) of participants achieved mycologic cure with efinaconazole versus 12.5% with vehicle (<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.001). Treatment&#x02010;related TEAE rates with efinaconazole were low (6.0%) and similar to the overall study population.</p></sec><sec id="myc70069-sec-0005"><title>Conclusions</title><p>Efinaconazole 10% solution showed similar efficacy/safety in participants aged &#x02265;&#x02009;65&#x02009;years to the overall phase 3 population, despite potential age&#x02010;related nail changes. These results demonstrate the benefits of efinaconazole in older patients with onychomycosis.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="myc70069-kwd-0001">clinical trial</kwd><kwd id="myc70069-kwd-0002">efinaconazole</kwd><kwd id="myc70069-kwd-0003">elderly</kwd><kwd id="myc70069-kwd-0004">onychomycosis</kwd><kwd id="myc70069-kwd-0005">toenail</kwd><kwd id="myc70069-kwd-0006">topical</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Ortho Dermatologics
</institution><institution-id institution-id-type="doi">10.13039/100019507</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="9"/><word-count count="5700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="myc70069-ntgp-0001"><fn fn-type="funding" id="myc70069-note-0001"><p>
<bold>Funding:</bold> This study was funded by Ortho Dermatologics.</p></fn></fn-group></notes></front><body id="myc70069-body-0001"><sec id="myc70069-sec-0006"><label>1</label><title>Introduction</title><p>Onychomycosis is a common, chronic fungal infection of the nail plate or bed that is caused by dermatophytes, nondermatophyte moulds (NDM), or yeasts [<xref rid="myc70069-bib-0001" ref-type="bibr">1</xref>]. Although it is a benign condition, onychomycosis can cause discomfort and pain and decreased quality of life; if untreated, it can lead to secondary infections and even amputations, particularly in diabetics [<xref rid="myc70069-bib-0002" ref-type="bibr">2</xref>]. Treatment of onychomycosis can be challenging because of reduced drug penetration owing to the thick nail plate, potential drug&#x02013;drug interactions and side effects, and lack of patient compliance [<xref rid="myc70069-bib-0001" ref-type="bibr">1</xref>, <xref rid="myc70069-bib-0002" ref-type="bibr">2</xref>, <xref rid="myc70069-bib-0003" ref-type="bibr">3</xref>, <xref rid="myc70069-bib-0004" ref-type="bibr">4</xref>]. Onychomycosis is more common in older adults [<xref rid="myc70069-bib-0005" ref-type="bibr">5</xref>], who may face additional therapeutic challenges due to slower nail growth, increased nail thickness, longer disease duration, comorbidities such as diabetes or peripheral vascular disease, and concomitant medication use [<xref rid="myc70069-bib-0003" ref-type="bibr">3</xref>, <xref rid="myc70069-bib-0006" ref-type="bibr">6</xref>, <xref rid="myc70069-bib-0007" ref-type="bibr">7</xref>, <xref rid="myc70069-bib-0008" ref-type="bibr">8</xref>]. Additionally, older adults may have reduced visual acuity and dexterity that could reduce compliance with topical treatments [<xref rid="myc70069-bib-0003" ref-type="bibr">3</xref>, <xref rid="myc70069-bib-0005" ref-type="bibr">5</xref>].</p><p>Oral terbinafine is often prescribed as a first&#x02010;line treatment for onychomycosis due to its good efficacy and low cost [<xref rid="myc70069-bib-0009" ref-type="bibr">9</xref>, <xref rid="myc70069-bib-0010" ref-type="bibr">10</xref>, <xref rid="myc70069-bib-0011" ref-type="bibr">11</xref>]. However, as rates of antifungal resistance rise globally, terbinafine may not be effective for all patients [<xref rid="myc70069-bib-0012" ref-type="bibr">12</xref>, <xref rid="myc70069-bib-0013" ref-type="bibr">13</xref>]. Other oral treatments approved in the US include itraconazole and griseofulvin, with fluconazole being prescribed off&#x02010;label [<xref rid="myc70069-bib-0001" ref-type="bibr">1</xref>]. Griseofulvin is rarely prescribed due to its inferior efficacy and greater recurrence rates compared with other oral treatments, and itraconazole has black box warnings for congestive heart failure, cardiac effects, and multiple drug&#x02013;drug interactions [<xref rid="myc70069-bib-0014" ref-type="bibr">14</xref>, <xref rid="myc70069-bib-0015" ref-type="bibr">15</xref>]. Furthermore, the use of oral medications in older adults can be complicated by contraindications, interactions with concomitant medications, and adverse effects, such as cardiac issues, hepatotoxicity, or liver enzyme abnormalities [<xref rid="myc70069-bib-0015" ref-type="bibr">15</xref>, <xref rid="myc70069-bib-0016" ref-type="bibr">16</xref>, <xref rid="myc70069-bib-0017" ref-type="bibr">17</xref>, <xref rid="myc70069-bib-0018" ref-type="bibr">18</xref>].</p><p>A 2021 therapeutic recommendations publication suggests that topical efinaconazole 10% solution may be beneficial as a first&#x02010;line treatment for most patients with onychomycosis, either as monotherapy or in combination with an oral antifungal [<xref rid="myc70069-bib-0001" ref-type="bibr">1</xref>]. In particular, for patients aged 65&#x02009;years and older, combination therapy with a topical such as efinaconazole and an oral agent such as terbinafine or fluconazole is recommended. When interactions with concomitant medications are a concern, efinaconazole alone may be preferable.</p><p>In two phase 3 clinical trials, topical efinaconazole 10% demonstrated good efficacy and safety in patients with mild to moderate toenail onychomycosis [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]. Here, we report post hoc analyses evaluating the efficacy and safety of once&#x02010;daily topical efinaconazole 10% solution in older adult study participants (aged &#x02265;&#x02009;65&#x02009;years).</p></sec><sec sec-type="methods" id="myc70069-sec-0007"><label>2</label><title>Methods</title><sec id="myc70069-sec-0008"><label>2.1</label><title>Study Design and Participants</title><p>Data were pooled from two multicenter, randomised, double&#x02010;blind, vehicle&#x02010;controlled, parallel&#x02010;group, phase 3 studies (NCT01008033 and NCT01007708), the details of which have been published previously [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]. Briefly, eligible participants aged 18&#x02013;70&#x02009;years with mild to moderate toenail distal lateral subungual onychomycosis (20%&#x02013;50% clinical involvement of the target toenail and no matrix involvement or dermatophytomas) affecting at least one great toenail were randomised (3:1) to topical efinaconazole 10% solution (Jublia; Ortho Dermatologics, Bridgewater, NJ) or vehicle solution self&#x02010;applied once daily for 48&#x02009;weeks. After a 4&#x02010;week treatment&#x02010;free period, a follow&#x02010;up visit was conducted at week 52. To evaluate the efficacy and safety of efinaconazole in older adults, a pooled post hoc analysis was conducted in participants aged &#x02265;&#x02009;65&#x02009;years.</p></sec><sec id="myc70069-sec-0009"><label>2.2</label><title>Ethics</title><p>The studies were conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki, and study protocols were approved by the ethics committee or institutional review board at all sites of investigation. All participants provided written informed consent prior to participation in the study.</p></sec><sec id="myc70069-sec-0010"><label>2.3</label><title>Assessments</title><p>Efficacy was determined by a combination of visual assessment of the percentage of affected toenail area (i.e., clinical involvement), potassium hydroxide (KOH) examination, and fungal culture of toenail samples taken at baseline and at weeks 12, 24, 36, 48, and 52. The primary efficacy endpoint was the rate of complete cure (no clinical involvement, negative KOH examination, and negative fungal culture of the target toenail) at week 52. Secondary efficacy endpoints included rates of mycologic cure (a negative KOH examination and a negative fungal culture of the target toenail), complete or almost complete cure (&#x02264;&#x02009;5% clinical involvement and mycologic cure), unaffected new toenail growth (change from baseline in the healthy/unaffected target toenail measurement), and clinical efficacy (&#x0003c;&#x02009;10% clinical involvement of the affected target nail) at week 52.</p><p>Participants also completed the OnyCOE&#x02010;t<sup>tm</sup> quality of life (QoL) questionnaire [<xref rid="myc70069-bib-0020" ref-type="bibr">20</xref>] at baseline, week 24, and week 52. The questionnaire comprises 33 questions across seven scales that assess toenail symptoms, problems with appearance, problems with physical activities, overall problems, stigma, and treatment satisfaction.</p><p>Adverse events (AEs) were monitored throughout the study.</p></sec><sec id="myc70069-sec-0011"><label>2.4</label><title>Statistical Analysis</title><p>The intent&#x02010;to&#x02010;treat (ITT) population included all randomised participants who were provided the study drug. The safety population included all randomised participants who used the study drug at least once and had at least one post&#x02010;baseline assessment. Post hoc analyses assessed only participants aged 65&#x02009;years and older.</p><p>Efficacy endpoints at week 52 were analysed using Cochran&#x02013;Mantel&#x02013;Haenszel tests stratified by analysis center at a significance level of 5%. Interpretation of the secondary endpoints of unaffected toenail growth and mycologic cure was performed in a sequential manner to adjust for multiplicity. Unaffected new toenail growth was considered statistically significant (active vs. vehicle) only if the complete or almost complete cure rate was statistically significant. The mycologic cure rate was considered statistically significant (active vs. vehicle) only if both the complete or almost complete cure rate and unaffected new toenail growth were statistically significant. The last observation carried forward method was used to impute missing efficacy data. All statistical analyses were performed using SAS. Statistical significance was only determined for week 52. Efficacy outcomes at weeks 12&#x02013;48 were summarised using descriptive statistics.</p><p>Treatment compliance (defined as not missing &#x0003e;&#x02009;14 cumulative doses in the 28&#x02009;days leading up to week 48, not missing &#x0003e;&#x02009;20% of the total number of expected doses during treatment, and/or not missing &#x02265;&#x02009;28 consecutive doses during treatment), safety, and QoL assessments were summarised using descriptive statistics. All items in the OnyCOE&#x02010;t QoL questionnaire were transformed to a 0 to 100 scale; higher scores indicated improved QoL.</p><p>All AEs were recorded and classified using Medical Dictionary for Regulatory Activities (version 12.1) terminology. No imputations were performed for missing safety data.</p></sec></sec><sec sec-type="results" id="myc70069-sec-0012"><label>3</label><title>Results</title><sec id="myc70069-sec-0013"><label>3.1</label><title>Participant Disposition and Demographics</title><p>Of the 1655 participants randomised in the two phase 3 studies [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>], 218 were aged 65&#x02013;71&#x02009;years (<italic toggle="yes">n</italic>&#x02009;=&#x02009;162 efinaconazole, <italic toggle="yes">n</italic>&#x02009;=&#x02009;56 vehicle). The majority were male (75.2%), and most were White (72.0%) and not Hispanic/Latino (90.4%; Table&#x000a0;<xref rid="myc70069-tbl-0001" ref-type="table">1</xref>). The mean area of target toenail involvement was 37.8%, and the mean number of affected nontarget toenails was 2.9. Approximately 89% of participants were treatment compliant.</p><table-wrap position="float" id="myc70069-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Demographic and baseline characteristics in patients aged &#x02265;&#x02009;65&#x02009;years (ITT population, pooled).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Efinaconazole 10% (<italic toggle="yes">n</italic>&#x02009;=&#x02009;162)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Vehicle (<italic toggle="yes">n</italic>&#x02009;=&#x02009;56)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean (range), year</td><td align="center" valign="top" rowspan="1" colspan="1">67.5 (65.0&#x02013;71.0<xref rid="myc70069-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">67.1 (65.0&#x02013;70.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">123 (75.9)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (73.2)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Race, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Asian</td><td align="center" valign="top" rowspan="1" colspan="1">43 (26.5)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (19.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Black</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">114 (70.4)</td><td align="center" valign="top" rowspan="1" colspan="1">43 (76.8)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other<xref rid="myc70069-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Ethnicity, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Not Hispanic or Latino</td><td align="center" valign="top" rowspan="1" colspan="1">149 (92.0)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (85.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Affected toenail, mean (range), %</td><td align="center" valign="top" rowspan="1" colspan="1">37.8 (20.0&#x02013;50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">37.9 (20.0&#x02013;50.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Affected nontarget toenails, mean (range), <italic toggle="yes">n</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.8 (0&#x02013;5.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3.3 (0&#x02013;5.0)</td></tr></tbody></table><table-wrap-foot id="myc70069-ntgp-0002"><fn id="myc70069-note-0002"><p>Abbreviation: ITT, intent to treat.</p></fn><fn id="myc70069-note-0003"><label>
<sup>a</sup>
</label><p>Participants may have turned 71&#x02009;years of age by the date of the baseline visit, which occurred 42&#x02009;days after screening owing to mycological testing. An additional 42&#x02010;day period could have occurred if further tests were required.</p></fn><fn id="myc70069-note-0004"><label>
<sup>b</sup>
</label><p>American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, and Other.</p></fn></table-wrap-foot></table-wrap></sec><sec id="myc70069-sec-0014"><label>3.2</label><title>Efficacy</title><p>At week 52, a significantly greater proportion of older adults treated with efinaconazole achieved complete cure versus vehicle (13.6% [<italic toggle="yes">n</italic>/<italic toggle="yes">N</italic>&#x02009;=&#x02009;22/162] vs. 3.6% [2/56]; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, Figure&#x000a0;<xref rid="myc70069-fig-0001" ref-type="fig">1A</xref>). A significantly greater percentage of participants achieved complete or almost complete cure with efinaconazole compared with vehicle at week 52 (19.1% [31/162] vs. 5.4% [3/56]; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01), with numerically higher rates observed at weeks 36 and 48 (week 36: 9.3% [15/162] vs. 0% [0/56]; week 48: 18.5% [30/162] vs. 3.6% [2/56]; Figure&#x000a0;<xref rid="myc70069-fig-0001" ref-type="fig">1B</xref>). Least squares mean unaffected new nail growth was significantly greater with efinaconazole versus vehicle at week 52 (3.9&#x02009;mm vs. 0&#x02009;mm; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001), and numerically greater with efinaconazole at all other time points (Figure&#x000a0;<xref rid="myc70069-fig-0002" ref-type="fig">2</xref>). More than half of older adults (59.3% [96/162]) achieved mycologic cure with efinaconazole at week 52, a significantly greater percentage than with vehicle (12.5% [7/56]; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001; Figure&#x000a0;<xref rid="myc70069-fig-0003" ref-type="fig">3</xref>). Almost half (49.4% [80/162]) of efinaconazole&#x02010;treated participants achieved mycologic cure as early as week 24. In addition, a quarter of participants treated with efinaconazole achieved clinical efficacy at week 52 (25.3% [41/162]) vs. 14.3% (8/56) of vehicle&#x02010;treated participants (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05; Figure&#x000a0;<xref rid="myc70069-fig-0004" ref-type="fig">4</xref>). Representative photographs of affected toenails from older adults treated with efinaconazole are shown in Figure&#x000a0;<xref rid="myc70069-fig-0005" ref-type="fig">5</xref>.</p><fig position="float" fig-type="FIGURE" id="myc70069-fig-0001"><label>FIGURE 1</label><caption><p>Complete cure (no clinical involvement and mycologic cure [negative KOH examination and negative fungal culture] of the target toenail) (A) and complete or almost complete cure (&#x02264;&#x02009;5% clinical involvement and mycologic cure [negative KOH examination and negative fungal culture]&#x000a0;of the target toenail) (B) by visit in patients aged &#x02265;&#x02009;65&#x02009;years (ITT population, pooled). *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01 vs. vehicle. Statistical significance was only determined for week 52 because the study was not powered for subgroup analyses. Complete cure and complete/almost complete cure rates at week 52 with efinaconazole in the overall phase 3 populations were 17.8% and 15.2% and 26.4% and 23.4%, respectively [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]. ITT, intent to treat; KOH, potassium hydroxide.</p></caption><graphic xlink:href="MYC-68-e70069-g005" position="anchor" id="jats-graphic-1"/></fig><fig position="float" fig-type="FIGURE" id="myc70069-fig-0002"><label>FIGURE 2</label><caption><p>Unaffected new toenail growth (change from baseline in the healthy [unaffected] toenail measurement of the target toenail) by visit in patients aged &#x02265;&#x02009;65&#x02009;years (ITT population, pooled). ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. vehicle. Statistical significance was only determined for week 52 because the study was not powered for subgroup analyses. Mean unaffected new toenail growth at week 52 with efinaconazole in the overall phase 3 populations was 5.0&#x02009;mm and 3.8&#x02009;mm [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]. LS, least squares; ITT, intent to treat.</p></caption><graphic xlink:href="MYC-68-e70069-g004" position="anchor" id="jats-graphic-3"/></fig><fig position="float" fig-type="FIGURE" id="myc70069-fig-0003"><label>FIGURE 3</label><caption><p>Mycologic cure (negative KOH examination and negative fungal culture of the target toenail) by visit in patients aged &#x02265;&#x02009;65&#x02009;years (ITT population, pooled). ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. vehicle. Statistical significance was only determined for week 52 because the study was not powered for subgroup analyses. Interpretation was performed in a sequential manner to adjust for multiplicity: Mycologic cure rate was considered statistically significant only if complete/almost complete cure rate <italic toggle="yes">and</italic> unaffected new toenail growth were significant. Mycologic cure rates at week 52 with efinaconazole in the overall phase 3 populations were 55.2% and 53.4% [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]. ITT, intent to treat; KOH, potassium hydroxide.</p></caption><graphic xlink:href="MYC-68-e70069-g003" position="anchor" id="jats-graphic-5"/></fig><fig position="float" fig-type="FIGURE" id="myc70069-fig-0004"><label>FIGURE 4</label><caption><p>Clinical efficacy (&#x0003c;&#x02009;10% involvement of the target toenail) by visit in patients aged &#x02265;&#x02009;65&#x02009;years (ITT population, pooled). *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. vehicle. Statistical significance was only determined for week 52 because the study was not powered for subgroup analyses. Clinical efficacy rates at week 52 with efinaconazole in the overall phase 3 populations were 35.7% and 31.0% [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]. ITT, intent to treat.</p></caption><graphic xlink:href="MYC-68-e70069-g001" position="anchor" id="jats-graphic-7"/></fig><fig position="float" fig-type="FIGURE" id="myc70069-fig-0005"><label>FIGURE 5</label><caption><p>Representative photographs from three patients aged &#x02265;&#x02009;65&#x02009;years treated with efinaconazole 10% for 48&#x02009;weeks. Individual results may vary. Photographic Images 2025<sup>&#x000a9;</sup>. Courtesy of Ortho Dermatologics Study Investigators. <sup>&#x02020;</sup>No clinical involvement of the target toenail and mycologic cure (negative KOH examination and negative fungal culture) of the target toenail. <sup>&#x02021;</sup>&#x02264;&#x02009;5% clinical involvement and mycologic cure (negative KOH examination and negative fungal culture) of the target toenail. <sup>&#x000a7;</sup>Negative KOH examination and negative fungal culture of the target toenail. <sup>&#x0204b;</sup>&#x0003c;&#x02009;10% involvement of the target toenail. KOH, potassium hydroxide.</p></caption><graphic xlink:href="MYC-68-e70069-g002" position="anchor" id="jats-graphic-9"/></fig></sec><sec id="myc70069-sec-0015"><label>3.3</label><title>Quality of Life</title><p>The mean change from baseline in all OnyCOE&#x02010;t scale scores at weeks 24 and 52 was generally numerically greater (indicating improvement) among participants treated with efinaconazole than those treated with vehicle (Table&#x000a0;<xref rid="myc70069-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="myc70069-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Mean (SD) change from baseline to weeks 24 and 52 in OnyCOE&#x02010;t<sup>tm</sup> quality of life questionnaire in patients aged &#x02265;&#x02009;65&#x02009;years (ITT population, pooled).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Scale</th><th align="center" colspan="2" valign="bottom" rowspan="1">Week 24</th><th align="center" colspan="2" valign="bottom" rowspan="1">Week 52</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Efinaconazole 10%</th><th align="center" valign="bottom" rowspan="1" colspan="1">Vehicle</th><th align="center" valign="bottom" rowspan="1" colspan="1">Efinaconazole 10%</th><th align="center" valign="bottom" rowspan="1" colspan="1">Vehicle</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Symptom frequency</td><td align="center" valign="top" rowspan="1" colspan="1">28.3 (23.3)</td><td align="center" valign="top" rowspan="1" colspan="1">23.2 (23.3)</td><td align="center" valign="top" rowspan="1" colspan="1">25.0 (24.7)</td><td align="center" valign="top" rowspan="1" colspan="1">19.5 (26.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Symptom bothersomeness</td><td align="center" valign="top" rowspan="1" colspan="1">18.2 (21.2)</td><td align="center" valign="top" rowspan="1" colspan="1">14.5 (23.5)</td><td align="center" valign="top" rowspan="1" colspan="1">15.3 (19.1)</td><td align="center" valign="top" rowspan="1" colspan="1">10.0 (28.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Physical activity problems</td><td align="center" valign="top" rowspan="1" colspan="1">13.2 (20.8)</td><td align="center" valign="top" rowspan="1" colspan="1">13.1 (28.7)</td><td align="center" valign="top" rowspan="1" colspan="1">7.8 (23.5)</td><td align="center" valign="top" rowspan="1" colspan="1">17.2 (27.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Appearance problems</td><td align="center" valign="top" rowspan="1" colspan="1">17.0 (18.6)</td><td align="center" valign="top" rowspan="1" colspan="1">17.6 (30.1)</td><td align="center" valign="top" rowspan="1" colspan="1">14.3 (22.6)</td><td align="center" valign="top" rowspan="1" colspan="1">17.6 (26.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall problem</td><td align="center" valign="top" rowspan="1" colspan="1">17.0 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">15.3 (33.0)</td><td align="center" valign="top" rowspan="1" colspan="1">16.1 (32.1)</td><td align="center" valign="top" rowspan="1" colspan="1">19.6 (34.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stigma</td><td align="center" valign="top" rowspan="1" colspan="1">6.4 (16.5)</td><td align="center" valign="top" rowspan="1" colspan="1">9.1 (21.0)</td><td align="center" valign="top" rowspan="1" colspan="1">6.2 (21.2)</td><td align="center" valign="top" rowspan="1" colspan="1">2.9 (21.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment satisfaction</td><td align="center" valign="top" rowspan="1" colspan="1">70.2 (30.1)</td><td align="center" valign="top" rowspan="1" colspan="1">57.5 (33.0)</td><td align="center" valign="top" rowspan="1" colspan="1">73.9 (31.9)</td><td align="center" valign="top" rowspan="1" colspan="1">48.3 (37.4)</td></tr></tbody></table><table-wrap-foot id="myc70069-ntgp-0003"><fn id="myc70069-note-0005"><p>
<italic toggle="yes">Note:</italic> Higher mean change scores indicate improvement.</p></fn></table-wrap-foot></table-wrap></sec><sec id="myc70069-sec-0016"><label>3.4</label><title>Safety</title><p>The proportion of older adults who experienced treatment&#x02010;emergent AEs (TEAEs) through week 52 was slightly smaller with efinaconazole (67.9% [110/162]) than with vehicle (75.0% [42/56]). The majority of TEAEs were unrelated to the study drug (efinaconazole, 94.0%; vehicle, 98.6%; Table&#x000a0;<xref rid="myc70069-tbl-0003" ref-type="table">3</xref>), most were mild to moderate in severity, and the discontinuation rate due to AEs was low (&#x0003c;&#x02009;5%). The most common treatment&#x02010;related TEAE (reported in &#x02265;&#x02009;3% of participants in any treatment group) with efinaconazole was application site dermatitis (4.3%).</p><table-wrap position="float" id="myc70069-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Treatment&#x02010;emergent adverse events through week 52 in patients aged &#x02265;&#x02009;65&#x02009;years (safety population, pooled).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Participants, <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Efinaconazole 10% (<italic toggle="yes">n</italic>&#x02009;=&#x02009;162)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Vehicle (<italic toggle="yes">n</italic>&#x02009;=&#x02009;56)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Reporting any TEAE</td><td align="center" valign="top" rowspan="1" colspan="1">110 (67.9)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (75.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reporting any SAEs<xref rid="myc70069-note-0007" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">10 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (3.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Discontinued drug or study due to AE</td><td align="center" valign="top" rowspan="1" colspan="1">7 (4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.8)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">TEAE severity</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mild</td><td align="center" valign="top" rowspan="1" colspan="1">104 (41.9)</td><td align="center" valign="top" rowspan="1" colspan="1">61 (43.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Moderate</td><td align="center" valign="top" rowspan="1" colspan="1">130 (52.4)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (52.8)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Severe</td><td align="center" valign="top" rowspan="1" colspan="1">14 (5.6)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (4.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment&#x02010;related TEAEs</td><td align="center" valign="top" rowspan="1" colspan="1">15 (6.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.4)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Most common treatment&#x02010;related TEAEs<xref rid="myc70069-note-0008" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Application site dermatitis</td><td align="center" valign="top" rowspan="1" colspan="1">7 (4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot id="myc70069-ntgp-0004"><fn id="myc70069-note-0006"><p>Abbreviations: AE, adverse event; SAE, serious adverse event; TEAE, treatment&#x02010;emergent adverse event.</p></fn><fn id="myc70069-note-0007"><label>
<sup>a</sup>
</label><p>None of the SAEs were considered related to the study drug.</p></fn><fn id="myc70069-note-0008"><label>
<sup>b</sup>
</label><p>Reported in &#x02265;&#x02009;3% of participants in any treatment group.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="myc70069-sec-0017"><label>4</label><title>Discussion</title><p>Topical efinaconazole 10% solution showed good efficacy in older adults aged 65&#x02013;71&#x02009;years with mild to moderate onychomycosis, with a significantly greater percentage of participants achieving complete, complete or almost complete, or mycologic cure versus vehicle at week 52. Additionally, the rates of treatment&#x02010;related TEAEs and discontinuations due to AEs were low with efinaconazole, demonstrating a good safety profile in this population.</p><p>Oral antifungal treatments are often the standard of care for toenail onychomycosis and have demonstrated efficacy in older adults. In the open&#x02010;label randomised IRON&#x02010;CLAD study of oral terbinafine (250&#x02009;mg/d with or without debridement for 12&#x02009;weeks), mycologic cure and complete cure were achieved in 64% and 28% of patients aged &#x02265;&#x02009;65&#x02009;years (<italic toggle="yes">n</italic>&#x02009;=&#x02009;75), respectively, by week 48 [<xref rid="myc70069-bib-0021" ref-type="bibr">21</xref>]. In two studies of patients aged &#x02265;&#x02009;60&#x02009;years treated with terbinafine (<italic toggle="yes">n</italic>&#x02009;=&#x02009;50 and 15; 250&#x02009;mg/d for 12&#x02009;weeks), mycologic cure rates at week 78 were 64.0% and 93.3% [<xref rid="myc70069-bib-0022" ref-type="bibr">22</xref>, <xref rid="myc70069-bib-0023" ref-type="bibr">23</xref>]. One of these studies also included patients randomised to oral itraconazole (200&#x02009;mg pulse; <italic toggle="yes">n</italic>&#x02009;=&#x02009;51), with a mycologic cure rate of 62.7% at week 78; there were no significant differences in cure rates between terbinafine and itraconazole [<xref rid="myc70069-bib-0023" ref-type="bibr">23</xref>]. In a subgroup analysis of Japanese patients aged &#x02265;&#x02009;65&#x02009;years in a double&#x02010;blind, placebo&#x02010;controlled study of oral fosravuconazole (100&#x02009;mg/d for 12&#x02009;weeks; <italic toggle="yes">n</italic>&#x02009;=&#x02009;39), a complete cure rate (0% clinical involvement and mycologic cure) of 64% was observed at week 48 [<xref rid="myc70069-bib-0024" ref-type="bibr">24</xref>]. It is important to note that while terbinafine, itraconazole, and fosravuconazole were generally efficacious in these older adult populations, some studies used less&#x02010;stringent definitions of mycologic cure (i.e., negative culture only [<xref rid="myc70069-bib-0022" ref-type="bibr">22</xref>] or negative KOH only [<xref rid="myc70069-bib-0024" ref-type="bibr">24</xref>] vs. negative culture plus negative KOH [<xref rid="myc70069-bib-0021" ref-type="bibr">21</xref>, <xref rid="myc70069-bib-0023" ref-type="bibr">23</xref>]); as such, results should be interpreted with caution. Further, while these studies demonstrate the benefits of these treatments, the real&#x02010;world use of oral antifungals in older adults may be hindered by polypharmacy [<xref rid="myc70069-bib-0025" ref-type="bibr">25</xref>], contraindications and warnings/precautions (including black box warnings) [<xref rid="myc70069-bib-0015" ref-type="bibr">15</xref>, <xref rid="myc70069-bib-0016" ref-type="bibr">16</xref>], poor treatment response resulting from impaired peripheral circulation to the nails [<xref rid="myc70069-bib-0026" ref-type="bibr">26</xref>], and lack of patient compliance [<xref rid="myc70069-bib-0004" ref-type="bibr">4</xref>], as well as rising rates of global antifungal resistance to terbinafine [<xref rid="myc70069-bib-0012" ref-type="bibr">12</xref>, <xref rid="myc70069-bib-0013" ref-type="bibr">13</xref>]. To our knowledge, there are no published clinical trials of fluconazole or griseofulvin in the treatment of toenail onychomycosis in older adults.</p><p>Three topical agents have been approved in the US for the treatment of toenail onychomycosis: ciclopirox 8% lacquer, tavaborole 5% solution, and efinaconazole 10% solution [<xref rid="myc70069-bib-0014" ref-type="bibr">14</xref>]. In pivotal, phase 3, 52&#x02010;week clinical studies in patients with mild to moderate onychomycosis, higher rates of mycologic and complete cure were observed with efinaconazole (53.4% and 55.2%; 15.2% and 17.8%, respectively [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]) vs tavaborole (31.1% and 35.9%; 6.5% and 9.1% [<xref rid="myc70069-bib-0027" ref-type="bibr">27</xref>]) or ciclopirox (28.6% and 35.7%; 5.5% and 8.5% [<xref rid="myc70069-bib-0028" ref-type="bibr">28</xref>]). However, caution should be exercised when making comparisons across treatments, as these were not head&#x02010;to&#x02010;head studies. Efinaconazole has also demonstrated efficacy versus vehicle in pooled phase 3 post hoc analyses of patient sex, race/ethnicity, age, and baseline disease severity and in other special populations, including paediatric patients and patients with diabetes [<xref rid="myc70069-bib-0029" ref-type="bibr">29</xref>, <xref rid="myc70069-bib-0030" ref-type="bibr">30</xref>, <xref rid="myc70069-bib-0031" ref-type="bibr">31</xref>, <xref rid="myc70069-bib-0032" ref-type="bibr">32</xref>, <xref rid="myc70069-bib-0033" ref-type="bibr">33</xref>, <xref rid="myc70069-bib-0034" ref-type="bibr">34</xref>, <xref rid="myc70069-bib-0035" ref-type="bibr">35</xref>]. Unfortunately, there is a dearth of data on the efficacy of topical antifungals in older adults with onychomycosis. To our knowledge, only results for efinaconazole have been published [<xref rid="myc70069-bib-0036" ref-type="bibr">36</xref>, <xref rid="myc70069-bib-0037" ref-type="bibr">37</xref>]; US prescribing information for tavaborole states that no overall differences in safety or effectiveness were observed between older and younger clinical study participants (though greater sensitivity in some older individuals cannot be ruled out) [<xref rid="myc70069-bib-0038" ref-type="bibr">38</xref>].</p><p>The analyses presented here demonstrated that almost 60% of older adults treated with efinaconazole, ranging in age from 65 to 71&#x02009;years, achieved mycologic cure, and 13.6% achieved complete cure by week 52, which was similar to the overall populations in the two phase 3 studies (53.4% and 55.2%; 15.2% and 17.8%, respectively) [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]. This was also similar to mycologic cure rates seen in three of the four above&#x02010;mentioned studies of oral treatments in older patients (62%&#x02013;64%), though definitions of mycologic cure differed across studies [<xref rid="myc70069-bib-0021" ref-type="bibr">21</xref>, <xref rid="myc70069-bib-0023" ref-type="bibr">23</xref>, <xref rid="myc70069-bib-0024" ref-type="bibr">24</xref>]. It is possible that higher cure rates could be achieved with continued treatment, as toenails can be slow to grow, especially in some older adults [<xref rid="myc70069-bib-0002" ref-type="bibr">2</xref>, <xref rid="myc70069-bib-0007" ref-type="bibr">7</xref>]. In a 72&#x02010;week open&#x02010;label study of once&#x02010;daily efinaconazole in Japanese patients with severe onychomycosis, a subgroup of patients aged &#x02265;&#x02009;65&#x02009;years achieved a similar mycologic cure rate (60.2%) to that of the present analyses, but the complete cure rate (33.1%) was twice as high [<xref rid="myc70069-bib-0036" ref-type="bibr">36</xref>]. Similarly, a second 72&#x02010;week open&#x02010;label study of efinaconazole in Canada found mycologic cure rates of 57.9% in patients aged &#x02265;&#x02009;70&#x02009;years at 72&#x02009;weeks of treatment [<xref rid="myc70069-bib-0037" ref-type="bibr">37</xref>]. Although older adults with onychomycosis are considered more difficult to treat, these results, together with those of the present analyses, demonstrate that topical efinaconazole is efficacious in older adults.</p><p>Moreover, despite age&#x02010;related increases in nail thickness and possible longer disease duration, the rates of efficacy with efinaconazole in older patients were similar to those in the overall phase 3 populations, which included participants as young as 18&#x02009;years (overall mean age: 50.6&#x02009;years) [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>]. This most likely reflects the relatively low binding affinity of efinaconazole for keratin [<xref rid="myc70069-bib-0039" ref-type="bibr">39</xref>]. In&#x000a0;vitro, efinaconazole has greater free&#x02010;drug concentration and keratin release after incubation in a keratin suspension than topical ciclopirox 8% or amorolfine 5% (not approved for use in the US) [<xref rid="myc70069-bib-0039" ref-type="bibr">39</xref>]. Efinaconazole 10% also has shown superior transungual penetration compared with tavaborole 5% and ciclopirox 8% [<xref rid="myc70069-bib-0040" ref-type="bibr">40</xref>].</p><p>In these pooled post hoc analyses, efinaconazole was also well tolerated in older adults, similar to the overall phase 3 populations. TEAEs occurred in 67.9% of older adults treated with efinaconazole versus 64.5% and 66.0% in overall populations, with low rates of discontinuations due to AEs (4.3% of older adults versus 3.2% and 1.9% of all patients) [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>].</p><p>One possible limitation of the present studies is that treatment may need to be longer than 48&#x02009;weeks to achieve higher rates of complete or almost complete cure in older adults due to slower nail growth. While longer treatment duration could potentially increase the risk of adverse events, a long&#x02010;term study of efinaconazole in Japan showed that rates of related TEAEs (6.4%) and discontinuations due to AEs (5.0%) at week 72 were similar to those seen at week 52 in the overall population of the phase 3 studies of efinaconazole (related TEAEs, 8.2% and 7.3%; discontinuations due to AEs, 3.2% and 1.9%) [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>, <xref rid="myc70069-bib-0036" ref-type="bibr">36</xref>]. Another 72&#x02010;week study of efinaconazole treatment in Canada showed no additional safety signals in patients &#x02265;&#x02009;70&#x02009;years of age [<xref rid="myc70069-bib-0037" ref-type="bibr">37</xref>]. An additional limitation of the p was the relatively short (4&#x02010;week) follow&#x02010;up period following treatment cessation. A follow&#x02010;up period longer than 4&#x02009;weeks may also show greater efficacy rates. For example, further reductions in disease severity were observed in a small, open&#x02010;label study of 48&#x02009;weeks of efinaconazole treatment with follow&#x02010;ups at 12 and 24&#x02009;weeks post&#x02010;treatment [<xref rid="myc70069-bib-0041" ref-type="bibr">41</xref>]. Finally, it should be noted that the post hoc analyses presented here were not statistically powered for subgroup analyses.</p></sec><sec sec-type="conclusions" id="myc70069-sec-0018"><label>5</label><title>Conclusion</title><p>Once&#x02010;daily topical efinaconazole 10% solution is a safe and effective treatment for toenail onychomycosis in patients aged &#x02265;&#x02009;65&#x02009;years with mild to moderate toenail distal lateral subungual onychomycosis. Efinaconazole showed similar efficacy and safety to the overall phase 3 populations [<xref rid="myc70069-bib-0019" ref-type="bibr">19</xref>], despite potential age&#x02010;related changes in nail growth or thickness in the older adult population. These results, taken together with those of other post hoc analyses, demonstrate the benefits of efinaconazole in various patient populations with onychomycosis, including male, female, and Hispanic patients, as well as those with longer disease duration or concurrent diabetes [<xref rid="myc70069-bib-0042" ref-type="bibr">42</xref>].</p></sec><sec id="myc70069-sec-0025"><title>Author Contributions</title><p>
<bold>Shari R. Lipner:</bold> writing &#x02013; review and editing, writing &#x02013; original draft. <bold>Aditya K. Gupta:</bold> writing &#x02013; original draft, writing &#x02013; review and editing. <bold>Warren S. Joseph:</bold> writing &#x02013; original draft, writing &#x02013; review and editing. <bold>Boni Elewski:</bold> writing &#x02013; original draft, writing &#x02013; review and editing. <bold>Eric Guenin:</bold> writing &#x02013; original draft, writing &#x02013; review and editing. <bold>Tracey C. Vlahovic:</bold> writing &#x02013; review and editing, writing &#x02013; original draft.</p></sec><sec sec-type="COI-statement" id="myc70069-sec-0024"><title>Disclosure</title><p>Shari R. Lipner has served as a consultant for Moberg Pharmaceuticals and BelleTorus Corporation. Aditya K. Gupta has served as a consultant, speaker, and investigator for Ortho Dermatologics. Warren S. Joseph has served as a consultant and speaker for Ortho Dermatologics. Boni Elewski has provided clinical research support (research funding to University) for AbbVie, Anaptys&#x02010;Bio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Incyte, LEO Pharma, Lilly, Merck, Menlo, Novartis, Pfizer, Regeneron, Sun Pharma, Ortho Dermatologics, and Vanda and was a consultant (received honorarium) for Boehringer Ingelheim, Bristol Myers Squibb, Celgene, LEO Pharma, Lilly, Menlo, Novartis, Pfizer, Sun Pharma, Ortho Dermatologics, and Verrica. Eric Guenin is an employee of Ortho Dermatologics and may hold stock and/or stock options in its parent company. Tracey C. Vlahovic has served as an investigator and speaker for Ortho Dermatologics.</p></sec><sec id="myc70069-sec-0023"><title>Ethics Statement</title><p>The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to, and the appropriate ethical review committee approval has been received.</p></sec><sec sec-type="COI-statement" id="myc70069-sec-0019"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="myc70069-sec-0020"><title>Acknowledgements</title><p>This study was funded by Ortho Dermatologics. Medical writing and editorial support were provided by Alexander Simon and Lynn M. Anderson, PhD, from Citrus Health Group Inc. (Chicago, Illinois), with support from Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US LLC.</p></ack><sec sec-type="data-availability" id="myc70069-sec-0022"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="myc70069-bibl-0001"><title>References</title><ref id="myc70069-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="myc70069-cit-0001">
<string-name>
<given-names>S. R.</given-names>
<surname>Lipner</surname>
</string-name>, <string-name>
<given-names>W. S.</given-names>
<surname>Joseph</surname>
</string-name>, <string-name>
<given-names>T. C.</given-names>
<surname>Vlahovic</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US</article-title>,&#x0201d; <source>Journal of Drugs in Dermatology</source>
<volume>20</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>1076</fpage>&#x02013;<lpage>1084</lpage>, <pub-id pub-id-type="doi">10.36849/JDD.6291</pub-id>.<pub-id pub-id-type="pmid">34636509</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="myc70069-cit-0002">
<string-name>
<given-names>J. K.</given-names>
<surname>Christenson</surname>
</string-name>, <string-name>
<given-names>G. M.</given-names>
<surname>Peterson</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Naunton</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Challenges and Opportunities in the Management of Onychomycosis</article-title>,&#x0201d; <source>Journal of Fungi</source>
<volume>4</volume>, no. <issue>3</issue> (<year>2018</year>): <elocation-id>87</elocation-id>, <pub-id pub-id-type="doi">10.3390/jof4030087</pub-id>.<pub-id pub-id-type="pmid">30042327</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="myc70069-cit-0003">
<string-name>
<given-names>J. M.</given-names>
<surname>Falotico</surname>
</string-name> and <string-name>
<given-names>S. R.</given-names>
<surname>Lipner</surname>
</string-name>, &#x0201c;<article-title>Updated Perspectives on the Diagnosis and Management of Onychomycosis</article-title>,&#x0201d; <source>Clinical, Cosmetic and Investigational Dermatology</source>
<volume>15</volume> (<year>2022</year>): <fpage>1933</fpage>&#x02013;<lpage>1957</lpage>, <pub-id pub-id-type="doi">10.2147/CCID.S362635</pub-id>.<pub-id pub-id-type="pmid">36133401</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="myc70069-cit-0004">
<string-name>
<given-names>C. E.</given-names>
<surname>LaSenna</surname>
</string-name> and <string-name>
<given-names>A.</given-names>
<surname>Tosti</surname>
</string-name>, &#x0201c;<article-title>Patient Considerations in the Management of Toe Onychomycosis&#x02014;Role of Efinaconazole</article-title>,&#x0201d; <source>Patient Preference and Adherence</source>
<volume>9</volume> (<year>2015</year>): <fpage>887</fpage>&#x02013;<lpage>891</lpage>, <pub-id pub-id-type="doi">10.2147/PPA.S72701</pub-id>.<pub-id pub-id-type="pmid">26170638</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="myc70069-cit-0005">
<string-name>
<given-names>A. K.</given-names>
<surname>Gupta</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Venkataraman</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Talukder</surname>
</string-name>, &#x0201c;<article-title>Onychomycosis in Older Adults: Prevalence, Diagnosis, and Management</article-title>,&#x0201d; <source>Drugs &#x00026; Aging</source>
<volume>39</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>191</fpage>&#x02013;<lpage>198</lpage>, <pub-id pub-id-type="doi">10.1007/s40266-021-00917-8</pub-id>.<pub-id pub-id-type="pmid">35102533</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="myc70069-cit-0006">
<string-name>
<given-names>B.</given-names>
<surname>Sigurgeirsson</surname>
</string-name>, &#x0201c;<article-title>Prognostic Factors for Cure Following Treatment of Onychomycosis</article-title>,&#x0201d; <source>Journal of the European Academy of Dermatology and Venereology</source>
<volume>24</volume>, no. <issue>6</issue> (<year>2010</year>): <fpage>679</fpage>&#x02013;<lpage>684</lpage>, <pub-id pub-id-type="doi">10.1111/j.1468-3083.2009.03487.x</pub-id>.<pub-id pub-id-type="pmid">19929941</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="myc70069-cit-0007">
<string-name>
<given-names>S. J.</given-names>
<surname>Albucker</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Conway</surname>
</string-name>, and <string-name>
<given-names>S. R.</given-names>
<surname>Lipner</surname>
</string-name>, &#x0201c;<article-title>Nails in Older Adults</article-title>,&#x0201d; <source>Annals of Medicine</source>
<volume>56</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>2336989</elocation-id>, <pub-id pub-id-type="doi">10.1080/07853890.2024.2336989</pub-id>.<pub-id pub-id-type="pmid">38738374</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="myc70069-cit-0008">
<string-name>
<given-names>P.</given-names>
<surname>Rich</surname>
</string-name>, &#x0201c;<article-title>Efinaconazole Topical Solution, 10%: The Benefits of Treating Onychomycosis Early</article-title>,&#x0201d; <source>Journal of Drugs in Dermatology</source>
<volume>14</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>58</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">25607909</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="myc70069-cit-0009">
<string-name>
<given-names>S.</given-names>
<surname>Geizhals</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Cooley</surname>
</string-name>, and <string-name>
<given-names>S. R.</given-names>
<surname>Lipner</surname>
</string-name>, &#x0201c;<article-title>Diagnostic Testing for Onychomycosis: A Retrospective Study Over 17&#x02009;Years</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>83</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>239</fpage>&#x02013;<lpage>241</lpage>, <pub-id pub-id-type="doi">10.1016/j.jaad.2019.12.019</pub-id>.<pub-id pub-id-type="pmid">31846714</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="myc70069-cit-0010">
<string-name>
<given-names>S. J.</given-names>
<surname>Albucker</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Falotico</surname>
</string-name>, <string-name>
<given-names>Z. N.</given-names>
<surname>Choo</surname>
</string-name>, <string-name>
<given-names>J. T.</given-names>
<surname>Matushansky</surname>
</string-name>, and <string-name>
<given-names>S. R.</given-names>
<surname>Lipner</surname>
</string-name>, &#x0201c;<article-title>Risk Factors and Treatment Trends for Onychomycosis: A Case&#x02010;Control Study of Onychomycosis Patients in the All of Us Research Program</article-title>,&#x0201d; <source>Journal of Fungi</source>
<volume>9</volume>, no. <issue>7</issue> (<year>2023</year>): <elocation-id>712</elocation-id>, <pub-id pub-id-type="doi">10.3390/jof9070712</pub-id>.<pub-id pub-id-type="pmid">37504701</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="myc70069-cit-0011">
<string-name>
<given-names>A. K.</given-names>
<surname>Gupta</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>Paquet</surname>
</string-name>, &#x0201c;<article-title>Management of Onychomycosis in Canada in 2014</article-title>,&#x0201d; <source>Journal of Cutaneous Medicine and Surgery</source>
<volume>19</volume>, no. <issue>3</issue> (<year>2015</year>): <fpage>260</fpage>&#x02013;<lpage>273</lpage>, <pub-id pub-id-type="doi">10.2310/7750.2014.14090</pub-id>.<pub-id pub-id-type="pmid">25775640</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="myc70069-cit-0012">
<string-name>
<given-names>A. K.</given-names>
<surname>Gupta</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Elewski</surname>
</string-name>, <string-name>
<given-names>W. S.</given-names>
<surname>Joseph</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Treatment of Onychomycosis in an Era of Antifungal Resistance: Role for Antifungal Stewardship and Topical Antifungal Agents</article-title>,&#x0201d; <source>Mycoses</source>
<volume>67</volume>, no. <issue>1</issue> (<year>2023</year>): <elocation-id>e13683</elocation-id>, <pub-id pub-id-type="doi">10.1111/myc.13683</pub-id>.</mixed-citation></ref><ref id="myc70069-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="myc70069-cit-0013">
<string-name>
<given-names>T. S.</given-names>
<surname>McCormick</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>Ghannoum</surname>
</string-name>, &#x0201c;<article-title>Time to Think Antifungal Resistance Increased Antifungal Resistance Exacerbates the Burden of Fungal Infections Including Resistant Dermatomycoses</article-title>,&#x0201d; <source>Pathogens and Immunity</source>
<volume>8</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>158</fpage>&#x02013;<lpage>176</lpage>, <pub-id pub-id-type="doi">10.20411/pai.v8i2.656</pub-id>.<pub-id pub-id-type="pmid">38486922</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="myc70069-cit-0014">
<string-name>
<given-names>E.</given-names>
<surname>Axler</surname>
</string-name> and <string-name>
<given-names>S. R.</given-names>
<surname>Lipner</surname>
</string-name>, &#x0201c;<article-title>Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes</article-title>,&#x0201d; <source>Infection and Drug Resistance</source>
<volume>17</volume> (<year>2024</year>): <fpage>819</fpage>&#x02013;<lpage>843</lpage>, <pub-id pub-id-type="doi">10.2147/IDR.S431526</pub-id>.<pub-id pub-id-type="pmid">38463386</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0015"><label>15</label><mixed-citation publication-type="miscellaneous" id="myc70069-cit-0015">
<article-title>&#x0201c;Sporanox<sup>&#x000ae;</sup> (Itraconazole Oral Tablets),&#x0201d;</article-title> Full Prescribing Information, Stiefel Laboratories, Inc. (2010).</mixed-citation></ref><ref id="myc70069-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="myc70069-cit-0016">
<article-title>&#x0201c;Lamisil<sup>&#x000ae;</sup> (Terbinafine Hydrochloride Oral Tablets),&#x0201d;</article-title> Full Prescribing Information, Novartis Pharmaceuticals Corp. (<year>2019</year>).</mixed-citation></ref><ref id="myc70069-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="myc70069-cit-0017">
<article-title>&#x0201c;Diflucan<sup>&#x000ae;</sup> (Fluconazole Oral Tablets),&#x0201d;</article-title> Full Prescribing Information, Pfizer, Inc. (2011).</mixed-citation></ref><ref id="myc70069-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="myc70069-cit-0018">
<article-title>&#x0201c;Gris&#x02010;Peg<sup>&#x000ae;</sup> (Griseofulvin Ultramicrosize Oral Tablets),&#x0201d;</article-title> Full Prescribing Information, Valeant Pharmaceuticals North America LLC (<year>2016</year>).</mixed-citation></ref><ref id="myc70069-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="myc70069-cit-0019">
<string-name>
<given-names>B. E.</given-names>
<surname>Elewski</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Rich</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Pollak</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efinaconazole 10% Solution in the Treatment of Toenail Onychomycosis: Two Phase III Multicenter, Randomized, Double&#x02010;Blind Studies</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>68</volume>, no. <issue>4</issue> (<year>2013</year>): <fpage>600</fpage>&#x02013;<lpage>608</lpage>, <pub-id pub-id-type="doi">10.1016/j.jaad.2012.10.013</pub-id>.<pub-id pub-id-type="pmid">23177180</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="myc70069-cit-0020">
<string-name>
<given-names>L. P.</given-names>
<surname>Potter</surname>
</string-name>, <string-name>
<given-names>S. D.</given-names>
<surname>Mathias</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Raut</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Kianifard</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Tavakkol</surname>
</string-name>, &#x0201c;<article-title>The OnyCOE&#x02010;t Questionnaire: Responsiveness and Clinical Meaningfulness of a Patient&#x02010;Reported Outcomes Questionnaire for Toenail Onychomycosis</article-title>,&#x0201d; <source>Health and Quality of Life Outcomes</source>
<volume>4</volume> (<year>2006</year>): <elocation-id>50</elocation-id>, <pub-id pub-id-type="doi">10.1186/1477-7525-4-50</pub-id>.<pub-id pub-id-type="pmid">16911778</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="myc70069-cit-0021">
<string-name>
<given-names>A.</given-names>
<surname>Tavakkol</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Fellman</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Kianifard</surname>
</string-name>, &#x0201c;<article-title>Safety and Efficacy of Oral Terbinafine in the Treatment of Onychomycosis: Analysis of the Elderly Subgroup in Improving Results in ONychomycosis&#x02010;Concomitant Lamisil and Debridement (IRON&#x02010;CLAD), an Open&#x02010;Label, Randomized Trial</article-title>,&#x0201d; <source>American Journal of Geriatric Pharmacotherapy</source>
<volume>4</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>1</fpage>&#x02013;<lpage>13</lpage>, <pub-id pub-id-type="doi">10.1016/j.amjopharm.2005.12.012</pub-id>.<pub-id pub-id-type="pmid">16730616</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="myc70069-cit-0022">
<string-name>
<given-names>E. B.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>L. F.</given-names>
<surname>Stein</surname>
</string-name>, <string-name>
<given-names>D. P.</given-names>
<surname>Fivenson</surname>
</string-name>, and <string-name>
<given-names>E. S.</given-names>
<surname>Atillasoy</surname>
</string-name>, &#x0201c;<article-title>Clinical Trial: The Safety of Terbinafine in Patients Over the Age of 60&#x02009;Years: A Multicenter Trial in Onychomycosis of the Feet</article-title>,&#x0201d; <source>International Journal of Dermatology</source>
<volume>39</volume>, no. <issue>11</issue> (<year>2000</year>): <fpage>861</fpage>&#x02013;<lpage>864</lpage>, <pub-id pub-id-type="doi">10.1046/j.1365-4362.2000.00087-2.x</pub-id>.<pub-id pub-id-type="pmid">11123452</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="myc70069-cit-0023">
<string-name>
<given-names>A. K.</given-names>
<surname>Gupta</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Konnikov</surname>
</string-name>, and <string-name>
<given-names>C. W.</given-names>
<surname>Lynde</surname>
</string-name>, &#x0201c;<article-title>Single&#x02010;Blind, Randomized, Prospective Study on Terbinafine and Itraconazole for Treatment of Dermatophyte Toenail Onychomycosis in the Elderly</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>44</volume>, no. <issue>3</issue> (<year>2001</year>): <fpage>479</fpage>&#x02013;<lpage>484</lpage>, <pub-id pub-id-type="doi">10.1067/mjd.2001.110874</pub-id>.<pub-id pub-id-type="pmid">11209118</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="myc70069-cit-0024">
<string-name>
<given-names>S.</given-names>
<surname>Watanabe</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Tsubouchi</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Okubo</surname>
</string-name>, &#x0201c;<article-title>Efficacy and Safety of Fosravuconazole L&#x02010;Lysine Ethanolate, a Novel Oral Triazole Antifungal Agent, for the Treatment of Onychomycosis: A Multicenter, Double&#x02010;Blind, Randomized Phase III Study</article-title>,&#x0201d; <source>Journal of Dermatology</source>
<volume>45</volume>, no. <issue>10</issue> (<year>2018</year>): <fpage>1151</fpage>&#x02013;<lpage>1159</lpage>, <pub-id pub-id-type="doi">10.1111/1346-8138.14607</pub-id>.<pub-id pub-id-type="pmid">30156314</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="myc70069-cit-0025">
<string-name>
<given-names>B.</given-names>
<surname>Elewski</surname>
</string-name> and <string-name>
<given-names>A.</given-names>
<surname>Tavakkol</surname>
</string-name>, &#x0201c;<article-title>Safety and Tolerability of Oral Antifungal Agents in the Treatment of Fungal Nail Disease: A Proven Reality</article-title>,&#x0201d; <source>Therapeutics and Clinical Risk Management</source>
<volume>1</volume>, no. <issue>4</issue> (<year>2005</year>): <fpage>299</fpage>&#x02013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">18360572</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="myc70069-cit-0026">
<string-name>
<given-names>N.</given-names>
<surname>Maskan Bermudez</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Rodriguez&#x02010;Tamez</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Perez</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Tosti</surname>
</string-name>, &#x0201c;<article-title>Onychomycosis: Old and New</article-title>,&#x0201d; <source>Journal of Fungi</source>
<volume>9</volume>, no. <issue>5</issue> (<year>2023</year>): <elocation-id>559</elocation-id>, <pub-id pub-id-type="doi">10.3390/jof9050559</pub-id>.<pub-id pub-id-type="pmid">37233270</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="myc70069-cit-0027">
<string-name>
<given-names>B. E.</given-names>
<surname>Elewski</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Aly</surname>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Baldwin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy and Safety of Tavaborole Topical Solution, 5%, a Novel Boron&#x02010;Based Antifungal Agent, for the Treatment of Toenail Onychomycosis: Results From 2 Randomized Phase&#x02010;III Studies</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>73</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>62</fpage>&#x02013;<lpage>69</lpage>, <pub-id pub-id-type="doi">10.1016/j.jaad.2015.04.010</pub-id>.<pub-id pub-id-type="pmid">25956661</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="myc70069-cit-0028">
<string-name>
<given-names>A. K.</given-names>
<surname>Gupta</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Fleckman</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Baran</surname>
</string-name>, &#x0201c;<article-title>Ciclopirox Nail Lacquer Topical Solution 8% in the Treatment of Toenail Onychomycosis</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>43</volume>, no. <issue>4 Suppl</issue> (<year>2000</year>): <fpage>S70</fpage>&#x02013;<lpage>S80</lpage>, <pub-id pub-id-type="doi">10.1067/mjd.2000.109071</pub-id>.<pub-id pub-id-type="pmid">11051136</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="myc70069-cit-0029">
<string-name>
<given-names>A. K.</given-names>
<surname>Gupta</surname>
</string-name>, <string-name>
<given-names>B. E.</given-names>
<surname>Elewski</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Sugarman</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Efficacy and Safety of Efinaconazole 10% Solution for Treatment of Mild to Moderate Onychomycosis: A Pooled Analysis of Two Phase 3 Randomized Trials</article-title>,&#x0201d; <source>Journal of Drugs in Dermatology</source>
<volume>13</volume>, no. <issue>7</issue> (<year>2014</year>): <fpage>815</fpage>&#x02013;<lpage>820</lpage>.<pub-id pub-id-type="pmid">25007364</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="myc70069-cit-0030">
<string-name>
<given-names>N.</given-names>
<surname>Bhatia</surname>
</string-name>, &#x0201c;<article-title>Managing Assessments and Expectations: Patient Responses Following Therapy With Efinaconazole Topical Solution, 10%</article-title>,&#x0201d; <source>Journal of Drugs in Dermatology</source>
<volume>14</volume>, no. <issue>7</issue> (<year>2015</year>): <fpage>694</fpage>&#x02013;<lpage>698</lpage>.<pub-id pub-id-type="pmid">26151785</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="myc70069-cit-0031">
<string-name>
<given-names>T.</given-names>
<surname>Rosen</surname>
</string-name>, &#x0201c;<article-title>Evaluation of Gender as a Clinically Relevant Outcome Variable in the Treatment of Onychomycosis With Efinaconazole Topical Solution 10%</article-title>,&#x0201d; <source>Cutis</source>
<volume>96</volume> (<year>2015</year>): <fpage>197</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">26562270</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="myc70069-cit-0032">
<string-name>
<given-names>F. E.</given-names>
<surname>Cook&#x02010;Bolden</surname>
</string-name> and <string-name>
<given-names>T.</given-names>
<surname>Lin</surname>
</string-name>, &#x0201c;<article-title>Efinaconazole Solution 10% for Treatment of Toenail Onychomycosis in Latino Patients</article-title>,&#x0201d; <source>Cutis</source>
<volume>99</volume>, no. <issue>4</issue> (<year>2017</year>): <fpage>286</fpage>&#x02013;<lpage>289</lpage>.<pub-id pub-id-type="pmid">28492600</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="myc70069-cit-0033">
<string-name>
<given-names>J. Q.</given-names>
<surname>Del Rosso</surname>
</string-name>, &#x0201c;<article-title>Onychomycosis of Toenails and Post&#x02010;Hoc Analyses With Efinaconazole 10% Solution Once&#x02010;Daily Treatment: Impact of Disease Severity and Other Concomitant Associated Factors on Selection of Therapy and Therapeutic Outcomes</article-title>,&#x0201d; <source>Journal of Clinical and Aesthetic Dermatology</source>
<volume>9</volume>, no. <issue>2</issue> (<year>2016</year>): <fpage>42</fpage>&#x02013;<lpage>47</lpage>.</mixed-citation></ref><ref id="myc70069-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="myc70069-cit-0034">
<string-name>
<given-names>T. C.</given-names>
<surname>Vlahovic</surname>
</string-name> and <string-name>
<given-names>W. S.</given-names>
<surname>Joseph</surname>
</string-name>, &#x0201c;<article-title>Efinaconazole Topical, 10% for the Treatment of Toenail Onychomycosis in Patients With Diabetes</article-title>,&#x0201d; <source>Journal of Drugs in Dermatology</source>
<volume>13</volume>, no. <issue>10</issue> (<year>2014</year>): <fpage>1186</fpage>&#x02013;<lpage>1190</lpage>.<pub-id pub-id-type="pmid">25607552</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="myc70069-cit-0035">
<string-name>
<given-names>L. F.</given-names>
<surname>Eichenfield</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Elewski</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Sugarman</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients: Open&#x02010;Label Phase 4 Study</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>84</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>1140</fpage>&#x02013;<lpage>1142</lpage>, <pub-id pub-id-type="doi">10.1016/j.jaad.2020.06.1004</pub-id>.<pub-id pub-id-type="pmid">32622145</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="myc70069-cit-0036">
<string-name>
<given-names>K.</given-names>
<surname>Iozumi</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Abe</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Ito</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy of Long&#x02010;Term Treatment With Efinaconazole 10% Solution in Patients With Onychomycosis, Including Severe Cases: A Multicenter, Single&#x02010;Arm Study</article-title>,&#x0201d; <source>Journal of Dermatology</source>
<volume>46</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>641</fpage>&#x02013;<lpage>651</lpage>, <pub-id pub-id-type="doi">10.1111/1346-8138.14935</pub-id>.<pub-id pub-id-type="pmid">31206779</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="myc70069-cit-0037">
<string-name>
<given-names>A. K.</given-names>
<surname>Gupta</surname>
</string-name> and <string-name>
<given-names>E. A.</given-names>
<surname>Cooper</surname>
</string-name>, &#x0201c;<article-title>Long&#x02010;Term Efficacy and Safety of Once&#x02010;Daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis</article-title>,&#x0201d; <source>Skin Therapy Letter</source>
<volume>26</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>5</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="myc70069-bib-0038"><label>38</label><mixed-citation publication-type="miscellaneous" id="myc70069-cit-0038">
<article-title>&#x0201c;Kerydin<sup>&#x000ae;</sup> (Tavaborole Topical Solution),&#x0201d;</article-title> Full Prescribing Information, Pfizer Inc. (<year>2018</year>).</mixed-citation></ref><ref id="myc70069-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="myc70069-cit-0039">
<string-name>
<given-names>K.</given-names>
<surname>Sugiura</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Sugimoto</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Hosaka</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Low Keratin Affinity of Efinaconazole Contributes to Its Nail Penetration and Fungicidal Activity in Topical Onychomycosis Treatment</article-title>,&#x0201d; <source>Antimicrobial Agents and Chemotherapy</source>
<volume>58</volume>, no. <issue>7</issue> (<year>2014</year>): <fpage>3837</fpage>&#x02013;<lpage>3842</lpage>, <pub-id pub-id-type="doi">10.1128/AAC.00111-14</pub-id>.<pub-id pub-id-type="pmid">24752277</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="myc70069-cit-0040">
<string-name>
<given-names>A.</given-names>
<surname>Elabbasi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kadry</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Joseph</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Elewski</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ghannoum</surname>
</string-name>, &#x0201c;<article-title>Transungual Penetration and Antifungal Activity of Prescription and Over&#x02010;The&#x02010;Counter Topical Antifungals: Ex&#x000a0;Vivo Comparison</article-title>,&#x0201d; <source>Dermatology and Therapy</source>
<volume>14</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>2495</fpage>&#x02013;<lpage>2507</lpage>, <pub-id pub-id-type="doi">10.1007/s13555-024-01237-6</pub-id>.<pub-id pub-id-type="pmid">39133361</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="myc70069-cit-0041">
<string-name>
<given-names>R. A.</given-names>
<surname>Pollak</surname>
</string-name> and <string-name>
<given-names>C.</given-names>
<surname>Ilie</surname>
</string-name>, &#x0201c;<article-title>Long&#x02010;Term Follow&#x02010;Up of Onychomycosis Patients Treated With Efinaconazole</article-title>,&#x0201d; <source>Journal of Drugs in Dermatology</source>
<volume>16</volume>, no. <issue>12</issue> (<year>2017</year>): <fpage>1269</fpage>&#x02013;<lpage>1273</lpage>.<pub-id pub-id-type="pmid">29240863</pub-id>
</mixed-citation></ref><ref id="myc70069-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="myc70069-cit-0042">
<string-name>
<given-names>T. C.</given-names>
<surname>Vlahovic</surname>
</string-name> and <string-name>
<given-names>A. K.</given-names>
<surname>Gupta</surname>
</string-name>, &#x0201c;<article-title>Efinaconazole Topical Solution (10%) for the Treatment of Onychomycosis in Adult and Pediatric Patients</article-title>,&#x0201d; <source>Expert Review of Anti&#x02010;Infective Therapy</source>
<volume>20</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>3</fpage>&#x02013;<lpage>15</lpage>, <pub-id pub-id-type="doi">10.1080/14787210.2021.1939011</pub-id>.<pub-id pub-id-type="pmid">34106031</pub-id>
</mixed-citation></ref></ref-list></back></article>